Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna’s preclinical cystic fibrosis (CF) human bronchial epithelial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results